{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T21:37:08Z","timestamp":1792791428520,"version":"4.5.0"},"reference-count":98,"publisher":"Spandidos Publications","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Exp Ther Med"],"DOI":"10.3892\/etm.2021.10770","type":"journal-article","created":{"date-parts":[[2021,9,20]],"date-time":"2021-09-20T12:44:23Z","timestamp":1632141863000},"source":"Crossref","is-referenced-by-count":53,"title":["Comprehensive review on the pathophysiology, clinical variants and management of pemphigus (Review)"],"prefix":"10.3892","volume":"22","author":[{"given":"Victor-Vlad","family":"Costan","sequence":"first","affiliation":[{"name":"Department of Oral and Maxillofacial Surgery, \u2018Grigore T. Popa\u2019 University of Medicine and Pharmacy, 700115 Ia\u0219i, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Popa","sequence":"additional","affiliation":[{"name":"Department of Oral Medicine and Oral Dermatology, \u2018Grigore T. Popa\u2019 University of Medicine and Pharmacy, 700115 Ia\u0219i, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M\u0103d\u0103lina","family":"H\u00e2ncu","sequence":"additional","affiliation":[{"name":"Department of Dermatology, \u2018Sf. Spiridon\u2019 Clinical Emergency County Hospital, 700111 Ia\u0219i, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Porumb\u2011Andrese","sequence":"additional","affiliation":[{"name":"Department of Dermatology, \u2018Grigore T. Popa\u2019 University of Medicine and Pharmacy, 700115 Ia\u0219i, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mihaela","family":"Toader","sequence":"additional","affiliation":[{"name":"Department of Oral Medicine and Oral Dermatology, \u2018Grigore T. Popa\u2019 University of Medicine and Pharmacy, 700115 Ia\u0219i, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2249","published-online":{"date-parts":[[2021,9,20]]},"reference":[{"key":"key20211014132756_b1-ETM-0-0-10770","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/j.clindermatol.2017.10.014","article-title":"Blistering diseases in the mature patient","volume":"36","author":"Lako\u0161 Juki\u0107","year":"2018","journal-title":"Clin Dermatol"},{"key":"key20211014132756_b2-ETM-0-0-10770","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1016\/j.jaad.2020.08.012","article-title":"COVID-19 outbreak and autoimmune bullous diseases: A systematic review of published cases","volume":"84","author":"Kasperkiewicz","year":"2021","journal-title":"J Am Acad Dermatol"},{"key":"key20211014132756_b3-ETM-0-0-10770","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1007\/s11882-007-0038-7","article-title":"What's new in blistering disorders?","volume":"7","author":"Chaudhari","year":"2007","journal-title":"Curr Allergy Asthma Rep"},{"key":"key20211014132756_b4-ETM-0-0-10770","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1111\/ddg.13688","article-title":"Bullous autoimmune dermatoses","volume":"16","author":"Hofmann","year":"2018","journal-title":"J Dtsch Dermatol Ges"},{"key":"key20211014132756_b5-ETM-0-0-10770","first-page":"1861","article-title":"Autoimmune bullous dermatoses: A review","volume":"65","author":"Bickle","year":"2002","journal-title":"Am Fam Physician"},{"key":"key20211014132756_b6-ETM-0-0-10770","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1111\/j.1749-6632.2009.04737.x","article-title":"Autoimmune bullous dermatoses: A review","volume":"1173","author":"Patr\u00edcio","year":"2009","journal-title":"Ann NY Acad Sci"},{"key":"key20211014132756_b7-ETM-0-0-10770","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1016\/j.jaci.2020.02.013","article-title":"Autoimmune bullous skin diseases, pemphigus and pemphigoid","volume":"145","author":"Egami","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"key20211014132756_b8-ETM-0-0-10770","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1111\/j.1610-0387.2011.07793.x","article-title":"Autoimmune bullous skin diseases. Part 1: Clinical manifestations","volume":"9","author":"Kneisel","year":"2011","journal-title":"J Dtsch Dermatol Ges"},{"issue":"17026","key":"key20211014132756_b9-ETM-0-0-10770","doi-asserted-by":"publisher","DOI":"10.1038\/nrdp.2017.26","article-title":"Pemphigus","volume":"3","author":"Kasperkiewicz","year":"2017","journal-title":"Nat Rev Dis Primers"},{"key":"key20211014132756_b10-ETM-0-0-10770","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s12016-017-8662-z","article-title":"Pemphigus: A comprehensive review on pathogenesis, clinical presentation and novel therapeutic approaches","volume":"54","author":"Pollmann","year":"2018","journal-title":"Clin Rev Allergy Immunol"},{"key":"key20211014132756_b11-ETM-0-0-10770","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1111\/ced.14041","article-title":"Pemphigus vulgaris and pemphigus foliaceus: An overview of the clinical presentation, investigations and management","volume":"44","author":"Melchionda","year":"2019","journal-title":"Clin Exp Dermatol"},{"issue":"1418","key":"key20211014132756_b12-ETM-0-0-10770","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.01418","article-title":"Pemphigus: Current and future therapeutic strategies","volume":"10","author":"Didona","year":"2019","journal-title":"Front Immunol"},{"key":"key20211014132756_b13-ETM-0-0-10770","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1111\/j.1365-2133.2011.10463.x","article-title":"IgG-induced clustering of desmogleins 1 and 3 in skin of patients with pemphigus fits with the desmoglein nonassembly depletion hypothesis","volume":"165","author":"Oktarina","year":"2011","journal-title":"Br J Dermatol"},{"issue":"1190","key":"key20211014132756_b14-ETM-0-0-10770","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.01190","article-title":"Non-desmoglein antibodies in patients with pemphigus vulgaris","volume":"9","author":"Amber","year":"2018","journal-title":"Front Immunol"},{"key":"key20211014132756_b15-ETM-0-0-10770","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1111\/j.1365-2133.2012.11040.x","article-title":"Association between HLA-DRB1 polymorphisms and pemphigus vulgaris: A meta-analysis","volume":"167","author":"Yan","year":"2012","journal-title":"Br J Dermatol"},{"key":"key20211014132756_b16-ETM-0-0-10770","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1111\/odi.12639","article-title":"Oral mucous membrane pemphigoid and pemphigus vulgaris-a retrospective two-center cohort study","volume":"23","author":"Sultan","year":"2017","journal-title":"Oral Dis"},{"key":"key20211014132756_b17-ETM-0-0-10770","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1016\/j.autrev.2015.06.005","article-title":"Oral mucosal manifestations of autoimmune skin diseases","volume":"14","author":"Mustafa","year":"2015","journal-title":"Autoimmun Rev"},{"key":"key20211014132756_b18-ETM-0-0-10770","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1007\/s40257-019-00461-7","article-title":"Oral lesions in autoimmune bullous diseases: An Overview of clinical characteristics and diagnostic algorithm","volume":"20","author":"Rashid","year":"2019","journal-title":"Am J Clin Dermatol"},{"key":"key20211014132756_b19-ETM-0-0-10770","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1590\/1984-0462\/;2019;37;1;00004","article-title":"Neonatal pemphigus in an infant born to a mother with pemphigus vulgaris: A case report","volume":"37","author":"Carvalho","year":"2019","journal-title":"Rev Paul Pediatr"},{"key":"key20211014132756_b20-ETM-0-0-10770","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1016\/j.jaad.2008.10.025","article-title":"Neonatal pemphigus in an infant born to a mother with serologic evidence of both pemphigus vulgaris and gestational pemphigoid","volume":"60","author":"Panko","year":"2009","journal-title":"J Am Acad Dermatol"},{"key":"key20211014132756_b21-ETM-0-0-10770","doi-asserted-by":"publisher","first-page":"453","DOI":"10.5144\/0256-4947.2007.453","article-title":"Pemphigus vulgaris in a neonate","volume":"27","author":"Amer","year":"2007","journal-title":"Ann Saudi Med"},{"key":"key20211014132756_b22-ETM-0-0-10770","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1111\/j.1524-4725.2005.31050","article-title":"Pemphigus vegetans occurring in a split-thickness skin graft","volume":"31","author":"Huang","year":"2005","journal-title":"Dermatol Surg"},{"key":"key20211014132756_b23-ETM-0-0-10770","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1111\/j.1365-2133.1992.tb00131.x","article-title":"Pemphigus vegetans in a child","volume":"127","author":"Sillevis Smitt","year":"1992","journal-title":"Br J Dermatol"},{"issue":"210","key":"key20211014132756_b24-ETM-0-0-10770","doi-asserted-by":"publisher","DOI":"10.4103\/0019-5154.127712","article-title":"Localized pemphigus vegetans without mucosal involvement","volume":"59","author":"Jain","year":"2014","journal-title":"Indian J Dermatol"},{"key":"key20211014132756_b25-ETM-0-0-10770","doi-asserted-by":"publisher","first-page":"S310","DOI":"10.5021\/ad.2011.23.S3.S310","article-title":"The Neumann type of pemphigus vegetans treated with combination of dapsone and steroid","volume":"23 (Suppl 3)","author":"Son","year":"2011","journal-title":"Ann Dermatol"},{"key":"key20211014132756_b26-ETM-0-0-10770","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1111\/pde.13152","article-title":"Pediatric pemphigus herpetiformis: Case report and review of the literature","volume":"34","author":"Peterman","year":"2017","journal-title":"Pediatr Dermatol"},{"key":"key20211014132756_b27-ETM-0-0-10770","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1159\/000498939","article-title":"MPGN type 3 associated with pemphigus herpetiformis mimicking PGNMID and dermatitis herpetiformis","volume":"9","author":"Shimizu","year":"2019","journal-title":"Case Rep Nephrol Dial"},{"key":"key20211014132756_b28-ETM-0-0-10770","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1111\/j.1582-4934.2007.00033.x","article-title":"Immunopathology and molecular diagnosis of autoimmune bullous diseases","volume":"11","author":"Mihai","year":"2007","journal-title":"J Cell Mol Med"},{"key":"key20211014132756_b29-ETM-0-0-10770","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1590\/s0365-05962010000400010","article-title":"Direct and indirect immunofluorescence","volume":"85","author":"Aoki","year":"2010","journal-title":"An Bras Dermatol"},{"issue":"369546","key":"key20211014132756_b30-ETM-0-0-10770","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/369546","article-title":"Clinical relevance of autoantibodies in patients with autoimmune bullous dermatosis","volume":"2012","author":"Mih\u00e1lyi","year":"2012","journal-title":"Clin Dev Immunol"},{"issue":"1974","key":"key20211014132756_b31-ETM-0-0-10770","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.01974","article-title":"Serological diagnosis of autoimmune bullous skin diseases","volume":"10","author":"Saschenbrecker","year":"2019","journal-title":"Front Immunol"},{"key":"key20211014132756_b32-ETM-0-0-10770","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1001\/archdermatol.2009.9","article-title":"ELISA testing of anti-desmoglein 1 and 3 antibodies in the management of pemphigus","volume":"145","author":"Abasq","year":"2009","journal-title":"Arch Dermatol"},{"key":"key20211014132756_b33-ETM-0-0-10770","first-page":"53","article-title":"Desmoglein ELISA in the diagnosis of pemphigus and its correlation with the severity of pemphigus vulgaris","volume":"8","author":"Mortazavi","year":"2009","journal-title":"Iran J Allergy Asthma Immunol"},{"key":"key20211014132756_b34-ETM-0-0-10770","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.autrev.2012.07.006","article-title":"Diagnostic accuracy of enzyme-linked immunosorbent assays (ELISA) to detect anti-skin autoantibodies in autoimmune blistering skin diseases: A systematic review and meta-analysis","volume":"12","author":"Tampoia","year":"2012","journal-title":"Autoimmun Rev"},{"key":"key20211014132756_b35-ETM-0-0-10770","doi-asserted-by":"publisher","first-page":"231","DOI":"10.3109\/08916934.2014.976629","article-title":"Detailed profiling of anti-desmoglein autoantibodies identifies anti-Dsg1 reactivity as a key driver of disease activity and clinical expression in pemphigus vulgaris","volume":"48","author":"Naseer","year":"2015","journal-title":"Autoimmunity"},{"key":"key20211014132756_b36-ETM-0-0-10770","doi-asserted-by":"publisher","first-page":"3781","DOI":"10.1172\/JCI64413","article-title":"Pemphigus autoantibodies generated through somatic mutations target the desmoglein-3 cis-interface","volume":"122","author":"Di Zenzo","year":"2012","journal-title":"J Clin Invest"},{"key":"key20211014132756_b37-ETM-0-0-10770","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1016\/j.jaad.2016.11.039","article-title":"Correlation of antimuscarinic acetylcholine receptor antibody titers and antidesmoglein antibody titers with the severity of disease in patients with pemphigus","volume":"76","author":"Lakshmi","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"key20211014132756_b38-ETM-0-0-10770","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1111\/ced.12634","article-title":"Pemphigus and associated comorbidities: A cross-sectional study","volume":"40","author":"Heelan","year":"2015","journal-title":"Clin Exp Dermatol"},{"key":"key20211014132756_b39-ETM-0-0-10770","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1111\/bjd.13433","article-title":"Identification of a new disease cluster of pemphigus vulgaris with autoimmune thyroid disease, rheumatoid arthritis and type I diabetes","volume":"172","author":"Parameswaran","year":"2015","journal-title":"Br J Dermatol"},{"key":"key20211014132756_b40-ETM-0-0-10770","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1016\/j.jaad.2013.05.016","article-title":"Assessment of the rate of long-term complete remission off therapy in patients with pemphigus treated with different regimens including medium- and high-dose corticosteroids","volume":"69","author":"Almugairen","year":"2013","journal-title":"J Am Acad Dermatol"},{"key":"key20211014132756_b41-ETM-0-0-10770","doi-asserted-by":"publisher","first-page":"FD01","DOI":"10.7860\/JCDR\/2015\/12110.5939","article-title":"Multiple adverse effects of systemic corticosteroids: A case report","volume":"9","author":"Satyanarayanasetty","year":"2015","journal-title":"J Clin Diagn Res"},{"key":"key20211014132756_b42-ETM-0-0-10770","doi-asserted-by":"publisher","first-page":"2693","DOI":"10.1056\/NEJMc1508234","article-title":"Long-term remissions in recalcitrant pemphigus vulgaris","volume":"373","author":"Ahmed","year":"2015","journal-title":"N Engl J Med"},{"key":"key20211014132756_b43-ETM-0-0-10770","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.1001\/archderm.142.11.1447","article-title":"A comparison of oral methylprednisolone plus azathioprine or mycophenolate mofetil for the treatment of pemphigus","volume":"142","author":"Beissert","year":"2006","journal-title":"Arch Dermatol"},{"key":"key20211014132756_b44-ETM-0-0-10770","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1016\/j.jaad.2008.09.052","article-title":"A randomized double-blind trial of intravenous immunoglobulin for pemphigus","volume":"60","author":"Amagai","year":"2009","journal-title":"J Am Acad Dermatol"},{"key":"key20211014132756_b45-ETM-0-0-10770","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1111\/1744-9987.12557","article-title":"Evaluating the efficacy of double-filtration plasmapheresis in treating five patients with drug-resistant pemphigus","volume":"21","author":"Higashihara","year":"2017","journal-title":"Ther Apher Dial"},{"key":"key20211014132756_b46-ETM-0-0-10770","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1080\/08916930600972040","article-title":"Immunoadsorption in pemphigus","volume":"39","author":"Eming","year":"2006","journal-title":"Autoimmunity"},{"issue":"12","key":"key20211014132756_b47-ETM-0-0-10770","doi-asserted-by":"publisher","DOI":"10.1007\/s13317-017-0100-y","article-title":"Next-generation anti-CD20 monoclonal antibodies in autoimmune disease treatment","volume":"8","author":"Du","year":"2017","journal-title":"Auto Immun Highlights"},{"key":"key20211014132756_b48-ETM-0-0-10770","doi-asserted-by":"publisher","first-page":"928","DOI":"10.2340\/00015555-2116","article-title":"Efficacy of rituximab for pemphigus: A systematic review and meta-analysis of different regimens","volume":"95","author":"Wang","year":"2015","journal-title":"Acta Derm Venereol"},{"key":"key20211014132756_b49-ETM-0-0-10770","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/j.critrevonc.2015.09.001","article-title":"A molecular perspective on rituximab: A monoclonal antibody for B cell non Hodgkin lymphoma and other affections","volume":"97","author":"Seyfizadeh","year":"2016","journal-title":"Crit Rev Oncol Hematol"},{"key":"key20211014132756_b50-ETM-0-0-10770","doi-asserted-by":"publisher","first-page":"1772","DOI":"10.1056\/NEJMoa062930","article-title":"Treatment of pemphigus vulgaris with rituximab and intravenous immune globulin","volume":"355","author":"Ahmed","year":"2006","journal-title":"N Engl J Med"},{"key":"key20211014132756_b51-ETM-0-0-10770","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1111\/j.1749-6632.2009.04744.x","article-title":"Rituximab in severe pemphigus","volume":"1173","author":"Schmidt","year":"2009","journal-title":"Ann N Y Acad Sci"},{"key":"key20211014132756_b52-ETM-0-0-10770","doi-asserted-by":"publisher","first-page":"200","DOI":"10.2340\/00015555-1429","article-title":"Concurrent cytomegalovirus and herpes simplex virus infection in pemphigus vulgaris treated with rituximab and prednisolone","volume":"93","author":"Chiu","year":"2013","journal-title":"Acta Derm Venereol"},{"key":"key20211014132756_b53-ETM-0-0-10770","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1684\/ejd.2018.3373","article-title":"Pneumocystis jirovecii pneumonia infection in pemphigus patients treated with rituximab: An observational nationwide epidemiological study in Taiwan","volume":"28","author":"Wei","year":"2018","journal-title":"Eur J Dermatol"},{"key":"key20211014132756_b54-ETM-0-0-10770","doi-asserted-by":"publisher","first-page":"182","DOI":"10.4103\/0378-6323.168912","article-title":"The controversy of hepatitis C and rituximab: A multidisciplinary dilemma with implications for patients with pemphigus","volume":"82","author":"Amber","year":"2016","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"key20211014132756_b55-ETM-0-0-10770","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1007\/s40257-019-00497-9","article-title":"Rituximab: A review in pemphigus vulgaris","volume":"21","author":"Frampton","year":"2020","journal-title":"Am J Clin Dermatol"},{"key":"key20211014132756_b56-ETM-0-0-10770","first-page":"1338","article-title":"Successful treatment of pemphigus vulgaris with ofatumumab","volume":"17","author":"Rapp","year":"2018","journal-title":"J Drugs Dermatol"},{"key":"key20211014132756_b57-ETM-0-0-10770","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1001\/jamadermatol.2014.1939","article-title":"Subcutaneous veltuzumab, a humanized anti-CD20 antibody, in the treatment of refractory pemphigus vulgaris","volume":"150","author":"Ellebrecht","year":"2014","journal-title":"JAMA Dermatol"},{"key":"key20211014132756_b58-ETM-0-0-10770","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1001\/jamadermatol.2014.3674","article-title":"Intralesional rituximab in the treatment of refractory oral pemphigus vulgaris","volume":"151","author":"Vinay","year":"2015","journal-title":"JAMA Dermatol"},{"issue":"2532","key":"key20211014132756_b59-ETM-0-0-10770","doi-asserted-by":"publisher","DOI":"10.3390\/ijms18122532","article-title":"Paraneoplastic pemphigus: Insight into the autoimmune pathogenesis, clinical features and therapy","volume":"18","author":"Paolino","year":"2017","journal-title":"Int J Mol Sci"},{"key":"key20211014132756_b60-ETM-0-0-10770","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1038\/JID.2015.408","article-title":"Epiplakin is a paraneoplastic pemphigus autoantigen and related to bronchiolitis obliterans in Japanese patients","volume":"136","author":"Tsuchisaka","year":"2016","journal-title":"J Investig Dermatol"},{"key":"key20211014132756_b61-ETM-0-0-10770","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1111\/j.1365-4632.2011.04868.x","article-title":"Paraneoplastic autoimmune multiorgan syndrome: 20 years after","volume":"50","author":"Czernik","year":"2011","journal-title":"Int J Dermatol"},{"key":"key20211014132756_b62-ETM-0-0-10770","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1440-0960.2005.126_1.x","article-title":"Paraneoplastic pemphigus: A brief update","volume":"46","author":"Wade","year":"2005","journal-title":"Australas J Dermatol"},{"key":"key20211014132756_b63-ETM-0-0-10770","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/s0896-8411(02)00092-6","article-title":"Paraneoplastic pemphigus is associated with the DRB1*03 allele","volume":"20","author":"Martel","year":"2003","journal-title":"J Autoimmun"},{"issue":"1259","key":"key20211014132756_b64-ETM-0-0-10770","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.01259","article-title":"Paraneoplastic pemphigus: Paraneoplastic autoimmune disease of the skin and mucosa","volume":"10","author":"Kim","year":"2019","journal-title":"Front Immunol"},{"issue":"bcr2014208677","key":"key20211014132756_b65-ETM-0-0-10770","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2014-208677","article-title":"A middle-aged man presenting with unexplained mucosal erosions and progressive dyspnoea","volume":"2015","author":"Healy","year":"2015","journal-title":"BMJ Case Rep"},{"key":"key20211014132756_b66-ETM-0-0-10770","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1046\/j.1525-1470.2003.20311.x","article-title":"Paraneoplastic pemphigus with bronchiolitis obliterans in a child","volume":"20","author":"Mar","year":"2003","journal-title":"Pediatr Dermatol"},{"key":"key20211014132756_b67-ETM-0-0-10770","doi-asserted-by":"publisher","first-page":"291","DOI":"10.2147\/CCID.S100802","article-title":"Paraneoplastic pemphigus: A short review","volume":"9","author":"Wieczorek","year":"2016","journal-title":"Clin Cosmet Investig Dermatol"},{"key":"key20211014132756_b68-ETM-0-0-10770","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.jaad.2006.06.007","article-title":"Lichenoid paraneoplastic pemphigus in the absence of detectable antibodies","volume":"56","author":"Cummins","year":"2007","journal-title":"J Am Acad Dermatol"},{"key":"key20211014132756_b69-ETM-0-0-10770","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1111\/1523-1747.ep12607012","article-title":"Characterization of paraneoplastic pemphigus autoantigens by immunoblot analysis","volume":"104","author":"Hashimoto","year":"1995","journal-title":"J Invest Dermatol"},{"key":"key20211014132756_b70-ETM-0-0-10770","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1016\/j.det.2011.06.016","article-title":"Current management strategies in paraneoplastic pemphigus (paraneoplastic autoimmune multiorgan syndrome)","volume":"29","author":"Frew","year":"2011","journal-title":"Dermatol Clin"},{"key":"key20211014132756_b71-ETM-0-0-10770","doi-asserted-by":"publisher","first-page":"e240","DOI":"10.1111\/ajd.12615","article-title":"Successful use of Bruton's kinase inhibitor, ibrutinib, to control paraneoplastic pemphigus in a patient with paraneoplastic autoimmune multiorgan syndrome and chronic lymphocytic leukaemia","volume":"58","author":"Lee","year":"2017","journal-title":"Australas J Dermatol"},{"key":"key20211014132756_b72-ETM-0-0-10770","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1111\/j.1600-0609.2004.00280.x","article-title":"Alemtuzumab-induced remission of both severe paraneoplastic pemphigus and leukaemic bone marrow infiltration in a case of treatment-resistant B-cell chronic lymphocytic leukaemia","volume":"73","author":"Hohwy","year":"2004","journal-title":"Eur J Haematol"},{"key":"key20211014132756_b73-ETM-0-0-10770","doi-asserted-by":"publisher","first-page":"e77","DOI":"10.1097\/RHU.0000000000000675","article-title":"Tocilizumab cannot prevent the development of bronchiolitis obliterans in patients with Castleman disease-associated paraneoplastic pemphigus","volume":"25","author":"Gu","year":"2019","journal-title":"J Clin Rheumatol"},{"key":"key20211014132756_b74-ETM-0-0-10770","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/j.det.2011.03.012","article-title":"Diagnosis and clinical features of pemphigus foliaceus","volume":"29","author":"James","year":"2011","journal-title":"Dermatol Clin"},{"key":"key20211014132756_b75-ETM-0-0-10770","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1111\/1523-1747.ep12612836","article-title":"Comparative epidemiology of pemphigus in Tunisia and France: Unusual incidence of pemphigus foliaceus in young Tunisian women","volume":"104","author":"Bastuji-Garin","year":"1995","journal-title":"J Invest Dermatol"},{"key":"key20211014132756_b76-ETM-0-0-10770","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1046\/j.1523-1747.1998.00085.x","article-title":"Lack of mucosal involvement in pemphigus foliaceus may be due to low expression of desmoglein 1","volume":"110","author":"Shirakata","year":"1998","journal-title":"J Invest Dermatol"},{"key":"key20211014132756_b77-ETM-0-0-10770","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1111\/j.1468-3083.2009.03265.x","article-title":"Anti-desmoglein 1 antibodies in healthy related and unrelated subjects and patients with pemphigus foliaceus in endemic and non-endemic areas from Tunisia","volume":"23","author":"Abida","year":"2009","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"key20211014132756_b78-ETM-0-0-10770","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1001\/archderm.1981.01650030034016","article-title":"Penicillamine-induced pemphigus foliaceus. A fatal outcome","volume":"117","author":"Matkaluk","year":"1981","journal-title":"Arch Dermatol"},{"key":"key20211014132756_b79-ETM-0-0-10770","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1111\/j.1087-0024.2004.00833.x","article-title":"Environmental risk factors in endemic pemphigus foliaceus (fogo selvagem)","volume":"9","author":"Aoki","year":"2004","journal-title":"J Investig Dermatol Symp Proc"},{"key":"key20211014132756_b80-ETM-0-0-10770","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1016\/j.humimm.2010.04.001","article-title":"Polymorphisms in the 2q33 and 3q21 chromosome regions including T-cell coreceptor and ligand genes may influence susceptibility to pemphigus foliaceus","volume":"71","author":"Dalla-Costa","year":"2010","journal-title":"Hum Immunol"},{"key":"key20211014132756_b81-ETM-0-0-10770","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1001\/archderm.1980.01640310085028","article-title":"Pemphigus foliaceus resembling eruptive seborrheic keratoses","volume":"116","author":"Bruckner","year":"1980","journal-title":"Arch Dermatol"},{"key":"key20211014132756_b82-ETM-0-0-10770","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1001\/archderm.126.4.543","article-title":"Pemphigus erythematosus resembling multiple seborrheic keratoses","volume":"126","author":"Jacyk","year":"1990","journal-title":"Arch Dermatol"},{"key":"key20211014132756_b83-ETM-0-0-10770","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1067\/mjd.2002.119647","article-title":"Nonendemic pemphigus foliaceus in children","volume":"46","author":"Metry","year":"2002","journal-title":"J Am Acad Dermatol"},{"key":"key20211014132756_b84-ETM-0-0-10770","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1159\/000018239","article-title":"Pemphigus erythematosus: Detection of anti-desmoglein-1 antibodies by ELISA","volume":"199","author":"Gomi","year":"1999","journal-title":"Dermatology"},{"key":"key20211014132756_b85-ETM-0-0-10770","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1038\/jid.2008.189","article-title":"Development of an IgG4-based predictor of endemic pemphigus foliaceus (fogo selvagem)","volume":"129","author":"Qaqish","year":"2009","journal-title":"J Invest Dermatol"},{"key":"key20211014132756_b86-ETM-0-0-10770","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1111\/j.1600-0625.2010.01069.x","article-title":"Novel ELISA systems for antibodies to desmoglein 1 and 3: Correlation of disease activity with serum autoantibody levels in individual pemphigus patients","volume":"19","author":"Schmidt","year":"2010","journal-title":"Exp Dermatol"},{"key":"key20211014132756_b87-ETM-0-0-10770","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1590\/abd1806-4841.20143830","article-title":"The value of trichoscopy in the differential diagnosis of scalp lesions in pemphigus vulgaris and pemphigus foliaceus","volume":"89","author":"Sar-Pomian","year":"2014","journal-title":"An Bras Dermatol"},{"key":"key20211014132756_b88-ETM-0-0-10770","first-page":"174","article-title":"Steroid sparing effect of intravenous immunoglobulin therapy in patients with pemphigus foliaceus","volume":"12","author":"Sami","year":"2002","journal-title":"Eur J Dermatol"},{"key":"key20211014132756_b89-ETM-0-0-10770","doi-asserted-by":"publisher","first-page":"e120","DOI":"10.1111\/ajd.12510","article-title":"Systemic lupus erythematosus associated with myasthenia gravis, pemphigus foliaceus and chronic thyroiditis after thymectomy","volume":"58","author":"Sawamura","year":"2017","journal-title":"Australas J Dermatol"},{"key":"key20211014132756_b90-ETM-0-0-10770","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.1016\/j.jaad.2019.11.059","article-title":"IgA pemphigus: A systematic review","volume":"82","author":"Kridin","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"key20211014132756_b91-ETM-0-0-10770","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1001\/archdermatol.2009.224","article-title":"Subcorneal pustular dermatosis\u2013type IgA pemphigus with autoantibodies to desmocollins 1, 2, and 3","volume":"145","author":"D\u00fcker","year":"2009","journal-title":"Arch Dermatol"},{"key":"key20211014132756_b92-ETM-0-0-10770","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1007\/s40257-016-0202-8","article-title":"Subcorneal pustular dermatosis: A review of 30 years of progress","volume":"17","author":"Watts","year":"2016","journal-title":"Am J Clin Dermatol"},{"key":"key20211014132756_b93-ETM-0-0-10770","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1016\/0190-9622(90)70125-2","article-title":"Intraepidermal neutrophilic IgA dermatosis","volume":"22","author":"Kuan","year":"1990","journal-title":"J Am Acad Dermatol"},{"key":"key20211014132756_b94-ETM-0-0-10770","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1007\/s00508-010-1361-x","article-title":"IgA pemphigus associated with monoclonal gammopathy completely resolved after achievement of complete remission of multiple myeloma with bortezomib, cyclophosphamide and dexamethasone regimen","volume":"122","author":"Adam","year":"2010","journal-title":"Wien Klin Wochenschr"},{"key":"key20211014132756_b95-ETM-0-0-10770","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1684\/ejd.2012.1662","article-title":"Intraepidermal neutrophilic IgA pemphigus successfully treated with dapsone","volume":"22","author":"Hirata","year":"2012","journal-title":"Eur J Dermatol"},{"key":"key20211014132756_b96-ETM-0-0-10770","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1016\/j.jaad.2005.02.051","article-title":"Rapid response of IgA pemphigus of the subcorneal pustular dermatosis subtype to treatment with adalimumab and mycophenolate mofetil","volume":"53","author":"Howell","year":"2005","journal-title":"J Am Acad Dermatol"},{"key":"key20211014132756_b97-ETM-0-0-10770","doi-asserted-by":"publisher","first-page":"E31","DOI":"10.1016\/j.jinf.2004.08.009","article-title":"Regression of subcorneal pustular dermatosis type of IgA pemphigus lesions with azithromycin","volume":"51","author":"Bliziotis","year":"2005","journal-title":"J Infect"},{"key":"key20211014132756_b98-ETM-0-0-10770","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1067\/mjd.2000.104002","article-title":"Rapid response of IgA pemphigus of subcorneal pustular dermatosis type to treatment with isotretinoin","volume":"43","author":"Gruss","year":"2000","journal-title":"J Am Acad Dermatol"}],"container-title":["Experimental and Therapeutic Medicine"],"original-title":[],"deposited":{"date-parts":[[2021,10,14]],"date-time":"2021-10-14T15:33:58Z","timestamp":1634225638000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.spandidos-publications.com\/10.3892\/etm.2021.10770"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,20]]},"references-count":98,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2021,9,20]]}},"URL":"https:\/\/doi.org\/10.3892\/etm.2021.10770","relation":{},"ISSN":["1792-0981","1792-1015"],"issn-type":[{"value":"1792-0981","type":"print"},{"value":"1792-1015","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,20]]},"article-number":"1335"}}